Value proposition

Nanogenics is an innovative, research-based biotechnology company that specialises in developing bespoke, peptide-based vectors for gene therapy. Nanogenics is proud to introduce LipTideTM; an exciting custom-built delivery vehicle that can be modified to target different cell types and deliver different payloads for all gene therapy.

LipTideTM is a peptide nanoparticle that has already shown excellent in vivo efficacy across a range of models and delivery routes, including nebulised and systemic administration. The peptide component performs two functions: it binds the payload to form the core of the nanoparticle and it also triggers receptors on target cells, which cause the cell to take-in the nanoparticle. This targeted, receptor-mediated, active uptake means that LipTideTM can be used to deliver any type of nucleic acid payload, including gene editing tools and nucleic acid vaccines.

The greatest challenge facing researchers has been the inability to deliver nucleic acids into target cells with efficiency, specificity and minimal side effects and this is holding back the true potential of gene therapy. With LipTideTM, Nanogenics is helping to overcome this major challenge and making the promise of gene therapy a reality.

Nanogenics is interested in meeting potential clinical investment partners to discuss licencing opportunities for LipTideTM.

Contacts:

Alan Walker (Director Business Development): alan.walker@nanogenics.co.uk, mobile: 07590 259941

Simon Newman (Director Pre-Clinical Development): simon.newman@nanogenics.co.uk, mobile 07714041487